title: Ocular biocompatibility and structural integrity of micro- and nanostructured poly(caprolactone) films.
abstract: The identification of biomaterials that are well tolerated in the eye is important for the development of new ocular drug delivery devices and implants, and the application of micro- and nanoengineered devices to biomedical treatments is predicated on the long-term preservation within the target organ or tissue of the very small functional design elements. This study assesses the ocular tolerance and durability of micro- and nanostructured biopolymer thin films injected or implanted into the rabbit eye. Structured poly(caprolactone) (PCL) thin films were placed in adult rabbit eyes for survival studies, with serial ophthalmic examinations over 6 months. Morphologic abnormalities and device/tissue reactions were evaluated by histologic studies, and scanning electron microscopy (SEM) of films was used to determine the structural integrity. Structured PCL thin films (20- to 40-μm thick) were constructed to design specifications with 50-μm linear microgrooves or arrays of nanopores with ~30-nm diameters. After up to 9 months of ocular residency, SEM on devices retrieved from the eye showed preservation of micro- and nanostructural features. In ocular safety evaluations carried out over 6 months, serial examinations in 18 implanted eyes showed no evidence of chronic inflammation, cataractogenesis, or retinal toxicity. Postoperative ocular inflammation was seen in 67% of eyes for 1 week, and persistent corneal edema occurred in 1 eye. Histology revealed no ocular inflammation or morphologic abnormalities of ocular tissues. Thin-film/tissue responses such as cellular reaction, fibrosis, or surface biodeposits were not seen. Micro- and nanostructured PCL thin films exhibited acceptable ocular tolerance and maintained the structural integrity of design features while residing in the eye. Thin-film micro- and nanostructured PCL appears to be a feasible biomaterial for intraocular therapeutic applications.
authors: Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA 94158, USA.
authors: Daniel A
authors: DA
authors: Bernards
authors: Robert B
authors: RB
authors: Bhisitkul
authors: Paula
authors: P
authors: Wynn
authors: Mark R
authors: MR
authors: Steedman
authors: On-Tat
authors: OT
authors: Lee
authors: Fergus
authors: F
authors: Wong
authors: Somanus
authors: S
authors: Thoongsuwan
authors: Tejal A
authors: TA
authors: Desai
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage* / Q000737:chemistry; D005123:Eye / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D008422:Materials Testing / Q000379:methods*; D008863:Microspheres; D049329:Nanostructures / Q000008:administration & dosage* / Q000737:chemistry; D011091:Polyesters / Q000008:administration & dosage* / Q000737:chemistry; D011817:Rabbits
chemical_list: D001672:Biocompatible Materials; D011091:Polyesters; C016240:polycaprolactone
references: J Microencapsul. 2008 Aug;25(5):298-306
references: 18465301
references: Int J Pharm. 2011 Aug 30;415(1-2):73-82
references: 21641984
references: J Ocul Biol Dis Infor. 2008 Mar;1(1):19-29
references: 20072632
references: Ann Pharmacother. 2007 Mar;41(3):449-54
references: 17341531
references: Stem Cells Int. 2012;2012:454295
references: 22550509
references: Am J Ophthalmol. 2010 Aug;150(2):144-162.e2
references: 20670739
references: Macromol Biosci. 2007 Jun 7;7(6):767-83
references: 17541922
references: Int J Pharm. 2008 Feb 28;350(1-2):14-26
references: 18162341
references: Biomed Microdevices. 2010 Jun;12(3):363-9
references: 20077017
references: Adv Mater. 2010 Jun 4;22(21):2358-62
references: 20376851
references: J Pharm Pharm Sci. 2000 May-Aug;3(2):234-58
references: 10994037
references: Biomaterials. 2000 Dec;21(23):2475-90
references: 11055295
references: Langmuir. 2007 Nov 20;23(24):11960-3
references: 17941655
references: Curr Opin Ophthalmol. 2009 Nov;20(6):511-9
references: 19667987
references: Int J Pharm. 2009 Mar 18;369(1-2):170-5
references: 19028556
references: J Biomed Mater Res A. 2009 Dec;91(3):647-55
references: 18988278
references: Soft Matter. 2010 Jan 1;6(8):1621-1631
references: 22140398
references: Pharm Res. 2010 Oct;27(10):2043-53
references: 20535532
references: Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1192-201
references: 12601049
references: Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5403-20
references: 20980702
references: Chem Soc Rev. 2009 Dec;38(12):3484-504
references: 20449064
references: J Microencapsul. 1992 Apr-Jun;9(2):153-66
references: 1593398
references: Int J Pharm. 2008 Dec 8;364(2):298-327
references: 18621492
references: Expert Opin Drug Deliv. 2008 Jun;5(6):615-28
references: 18532918
references: Int J Pharm. 2008 Jan 4;346(1-2):151-9
references: 17681683
references: Acta Biomater. 2010 Sep;6(9):3566-72
references: 20350620
references: J Control Release. 2001 Jan 29;70(1-2):1-20
references: 11166403
references: Invest Ophthalmol Vis Sci. 2009 May;50(5):2312-8
references: 19117927
references: Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2126-34
references: 19834044
references: Int J Pharm. 2009 Oct 20;381(1):1-18
references: 19664700
references: Eur J Pharm Biopharm. 2008 Mar;68(3):637-46
references: 17851057
references: J Biomater Sci Polym Ed. 2011;22(4-6):443-56
references: 20566039
references: Biomaterials. 2008 Dec;29(36):4800-7
references: 18834628
references: J Biomed Mater Res A. 2005 Jun 15;73(4):437-44
references: 15900615
references: J Pharm Pharmacol. 2007 May;59(5):629-35
references: 17524227